



... 09-12-07 1FW

Express Mail No.: EB 132602574 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Wu, et al.	Confirmation No.:	3434
Serial No.:	10/781,442	Art Unit:	1626
Filed:	February 18, 2004	Examiner:	Shameem Golam, M.
For:	Phenylenediamine Urotensin-II Receptor Antagonists and CCR-9 Antagonists	Attorney Docket No.:	017092-0046-999 (CAM: 011104-999015)

STATEMENT OF SUBSTANCE OF INTERVIEW UNDER C.F.R. § 1.133(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants thank Examiner Golam Shameem for the telephonic interview held on July 17, 2007, and hereby submit a recordation of the substance of the interview within one month of the date of mailing of the Interview Summary Form.

The Interview Summary accurately reflects the substance of the interview. The issues discussed were cancellation of non-elected claims 7, 12, 14 and 15. Applicants' representative had agreed to cancel claims 7, 12, 14 and 15 without prejudice or disclaimer to facilitate the issuance of a patent based on the subject matter of the allowed claims: claims 6, 8, 11 and 13. Applicants reserve the right to file divisional applications to any canceled subject matter.

No fee is believed to be due with this statement. Nevertheless, pursuant to 37 C.F.R. § 1.136 (a)(3), the Commissioner is authorized to charge all required fees, or credit any overpayment, to Jones Day U.S. Deposit Account No. 503013 (referencing Attorney Docket No. 011104-999015).

Respectfully submitted,

Date: September 10, 2007


Dale L. Rieger

Reg. No. 43,045

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939